Results 191 to 200 of about 34,628,233 (409)

SAFE Homes statistical reports, Q4 SFY 2003

, 2001
Quarterly; 4/1/2001 to 6/30/2001-; Title from caption (viewed June 8, 2004).; Latest issue consulted: 01/01/2004 to 03/31/2004.; Issued in multiple vols.; Volumes for 4/1/2001 to 6/30/2001-10/1/2001 to 12/31/2001, 10/1/2003 to 12/31/2003- issued by Dept.
SAFE Homes (Program)
core  

Programming with Global Analysis

, 1997
Abstract is not ...
openaire   +2 more sources

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source

Darden Waiting Line Analysis Program (Queue): Quick Start-User's Manual

, 2009
John L. Colley, Michael J. Kennedy
openalex   +1 more source

SAFE Homes statistical reports, Q4 SFY 2002

, 2001
Quarterly; 4/1/2001 to 6/30/2001-; Title from caption (viewed June 8, 2004).; Latest issue consulted: 01/01/2004 to 03/31/2004.; Issued in multiple vols.; Volumes for 4/1/2001 to 6/30/2001-10/1/2001 to 12/31/2001, 10/1/2003 to 12/31/2003- issued by Dept.
SAFE Homes (Program)
core  

Heterozygous loss‐of‐function alleles associate the conserved 3′‐5′ exoribonuclease EXOSC10 with hypersensitivity to the anticancer drug 5‐fluorouracil

Molecular Oncology, EarlyView.
EXOSC10, an essential nuclear RNA exosome‐associated 3′‐5′ exoribonuclease, is inhibited by the anticancer drug 5‐fluorouracil (5‐FU), and EXOSC10 depletion increases 5‐FU sensitivity. The colon‐cancer variant EXOSC10S402T, located in a proteolysis motif, is stable and nuclear but nonfunctional in vivo.
Radhika Sain, Yann Le Page, Frédéric Percevault, Emmanuelle Becker, Luc Negroni, Almudena Fernandez, Marta Cantero, Diego Muñoz‐Santos, Lluís Montoliu, Cyrille Garnier, Michael Primig   +10 more
wiley   +1 more source

Demographic, Clinical, and Mortality Trends of Law Enforcement-Related Trauma: A Trauma Quality Improvement Program Analysis.

JAMA Surg, 2021
Bourdillon AT, Salehi PP, Lee JY, Steren B, Pei KY, Lee YH.   +5 more
europepmc   +1 more source

Women in MBA Programs at Top 20 US Business Schools: Trends Analysis for 19 Years (1999 to 2017)

, 2017
Ramesh Kotnana
openalex   +1 more source

Cell‐cycle‐specific lesion evolution rather than inhibition of double‐strand‐break repair underpins cisplatin radiosensitization

Molecular Oncology, EarlyView.
We analyze cisplatin–DNA adducts (CDAs) and double‐strand breaks (DSBs) in a cell‐cycle‐dependent manner. We find that CDAs form similarly across all cell cycle phases. DSBs arise only in S‐phase. CDAs might not directly impair DSB repair, but S‐phase DSB lesions evolve in the presence of CDAs and disrupt repair in G2, also causing radiosensitization ...
Ye Qiu, Xixi Lin, Emil Mladenov, Veronika Mladenova, Jürgen Thomale, Ali Sak, Yao Wang, Yunxuan Deng, Eleni Gkika, Martin Stuschke, George Iliakis   +10 more
wiley   +1 more source

Systemic Manifestations and Mortality Risk in Transthyretin V142I Variant Carriers: A Million Veteran Program Analysis. [PDF]

JACC CardioOncol
Sideris K, Nelson TJ, Brinker L, Gao A, Tcheandjieu C, Kyriakopoulos CP, Berlowitz D, Hull L, Ferraro JP, Agiri FY, Pridgen KM, Roblin S, Joseph J, Damrauer SM, Chang KM, Teerlink CC, Stehlik J, Carter S, Lynch JA.   +18 more
europepmc   +1 more source